Celltrion Pharm Achieves Record First-Quarter Results with 12.9 Billion Won Operating Profit

Celltrion Pharm announced on May 6 that in the first quarter of this year, it recorded sales of 132.1 billion won and operating profit of 12.9 billion won. Compared to the same period last year, sales increased by 17.4% and operating profit by 20.2%, marking the company's highest-ever first quarter performance.

This achievement reflects balanced growth across key business segments, including chemical, bio, and contract manufacturing operations. In particular, the expansion of sales in the bio and contract manufacturing segments led to an increase in operating profit, while the operating margin also rose by 0.2 percentage points year-on-year.

The chemical business segment posted sales of 54.4 billion won in the first quarter, representing a 5.5% increase from the same period last year. Sales of Godex, a liver supplement, rose by 8.8% to reach 17.6 billion won, while Dilatrend, a hypertension treatment, grew by 12.3% to 14.9 billion won, both driving overall sales growth. In addition, sales of the triple combination drug Amlojet for hypertension and hyperlipidemia increased by 32.0% year-on-year. These core product lines have maintained a stable trend, underpinning the performance of the chemical segment.

The bio business segment achieved sales of 33.4 billion won, up 60.1% compared to the same period last year. Remsima, an autoimmune disease treatment, posted sales of 12.7 billion won, a 37.6% year-on-year increase, driven by the approval of a higher-dose pen-type product. Truxima, a treatment for blood cancer, posted 3.7 billion won in sales, up 48.3%. Yuflyma, another autoimmune disease therapy, recorded sales of 2.6 billion won, a 103.5% increase. Vegzelma, an anticancer agent, saw sales jump by 168.3% to 3.9 billion won. Stoboclo, an osteoporosis treatment, also reported a significant rise in prescriptions and sales, soaring 300% year-on-year to 2.9 billion won. Additionally, products such as Omriclo, Aptosma, and Stekima have seen new prescriptions expand at major domestic hospitals, further driving the growth of the bio segment.

The contract manufacturing segment also recorded sales of 33.6 billion won, up 22% from the previous year. In particular, commercial sales of PFS (pre-filled syringes) reached 25.7 billion won, up 36.1% and leading growth in this segment. Internalized commercial sales also increased by 60.3% to 2.9 billion won. Celltrion Pharm continues to strengthen its competitiveness in contract manufacturing by improving production efficiency and enhancing its supply response capabilities.

Building on its record first quarter, Celltrion Pharm plans to further reinforce competitiveness in each business segment and continuously improve production and product operation efficiency to maintain stable performance into the second quarter. The company aims to solidify its sales growth foundation through stable sales of core chemical products, high growth of its biosimilar product lineup, and the expansion of PFS-focused contract manufacturing capabilities.

A Celltrion Pharm representative stated, "The first quarter of 2026 saw simultaneous improvements in both sales and profitability, thanks to the steady performance of the chemical segment and stronger growth momentum in the bio segment. We will continue to strengthen our competitiveness in each business area and expand our product portfolio to ensure a stable growth foundation throughout this year."

This content was produced with the assistance of AI translation services.